A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2002
12/10/2002	CA2074580C Solid pharmaceutical composition for oral administration containing dapiprazole
12/08/2002	CA2817619A1 Methods of administering anti-tnf.alpha. antibodies
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/06/2002	WO2002000605A1 Novel dicarboxylic acid derivatives
12/06/2002	CA2411059A1 Novel dicarboxylic acid derivatives
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097079A2 Gene encoding molecular motor protein and diagnosis method for the disease related to the gene
12/05/2002	WO2002097067A1 A method of purification of cells
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097046A2 B7 related protein-2 molecules and uses thereof
12/05/2002	WO2002097045A2 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/05/2002	WO2002097044A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	WO2002097035A2 Secreted proteins
12/05/2002	WO2002097033A2 Antibodies that immunospecifically bind to trail receptors
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002096952A2 Conjugate of a transport protein and a protein for modulation of notch signalling
12/05/2002	WO2002096951A1 Molecules for disease detection and treatment
12/05/2002	WO2002096937A2 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
12/05/2002	WO2002096934A1 Non-natural galanin receptor ligands
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096926A1 Modulators of pharmacological agents
12/05/2002	WO2002096912A1 Novel ligand for nicotinic acetylcholine receptors useful in therapy
12/05/2002	WO2002096911A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators
12/05/2002	WO2002096909A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
12/05/2002	WO2002096906A1 Aryl-8-azabicyclo[3.2.1]octanes for the treatment of depression
12/05/2002	WO2002096902A1 Carbazole derivatives and their use for the preparation of pharmaceutical compositions for the treatment of npy related diseases
12/05/2002	WO2002096897A1 PHOSPHINYLMETHYL AND PHOSPHORYLMETHYL SUCCINIC AND GLUTARIC ACID ANALOGS AS β-SECRETASE INHIBITORS
12/05/2002	WO2002096895A1 Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096888A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096881A1 Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide
12/05/2002	WO2002096879A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096858A1 Cinnamide derivatives as kcnq potassium channel modulators
12/05/2002	WO2002096855A2 Anticholinergic compounds and methods of use
12/05/2002	WO2002096467A2 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	WO2002096458A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	WO2002096456A1 Use of il-18 inhibitors for treating or preventing cns injuries
12/05/2002	WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	WO2002096442A1 Use of a product comprising catuama exptract as an antidepressant agent and in anxiety disorders
12/05/2002	WO2002096433A1 Methods for treating delirium using glucocorticoid receptor-specific antagonists
12/05/2002	WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096424A1 Hetereocyclic beta-aminoacids and their use as anti-epileptogenic agents
12/05/2002	WO2002096423A2 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
12/05/2002	WO2002096421A1 5-substituted-2-arylpyridines as crf1 modulators
12/05/2002	WO2002096420A2 Method for treating nerve injury caused by surgery
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096415A2 Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
12/05/2002	WO2002096411A1 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
12/05/2002	WO2002096409A1 Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain
12/05/2002	WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	WO2002096401A1 Solid pharmaceutical formulations comprising modafinil
12/05/2002	WO2002096368A2 Encapsulation of nanosuspensions in liposomes and microspheres
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096362A2 Method for treating fibrotic diseases or other indications vi
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096351A2 Ultrashort-acting opioids for transdermal application
12/05/2002	WO2002096350A2 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
12/05/2002	WO2002096224A1 Oral composition comprising an extract from the bark of albizzia myriophylla
12/05/2002	WO2002078693A3 N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002066043A3 Use of a polyfunctional active substance mixture as an antagonist against harmful substances contained in tobacco smoke
12/05/2002	WO2002065978A3 Functional agent for decomposing nicotine and method of preparing the same
12/05/2002	WO2002064547A3 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
12/05/2002	WO2002064124A3 Medicament formulation containing a muscarinic agonist
12/05/2002	WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
12/05/2002	WO2002060234A3 Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof
12/05/2002	WO2002059155A3 Modulation of calcium channel activity
12/05/2002	WO2002059150A3 Materials and methods relating to protein aggregation in neurodegenerative disease
12/05/2002	WO2002020766A3 G-csf analog compositions and methods
12/05/2002	WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002	WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002	WO2002006453A3 Regulation of human desc1-like serine protease
12/05/2002	WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002	WO2001090142A3 FULL LENGTH HUMAN HCN1 Ih CHANNEL SUBUNIT AND VARIANTS
12/05/2002	WO2001079448A3 Trp8, a transient receptor potential channel expressed in taste receptor cells
12/05/2002	WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules
12/05/2002	US20020183507 Novel human GABA receptor proteins and polynucleotides encoding the same
12/05/2002	US20020183391 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
12/05/2002	US20020183390 Administration of a D-serine transport inhibitor (serine dodecylamide, alanine dodecylamide or glycyldodecylamide) sufficient to enhance (N-methyl-D-aspartate) receptor mediated neurotransmission in vivo for psychological disorder
12/05/2002	US20020183389 Preferably at least 95%, is in the form of eicosapentaenoic acid (EPA), and less than 5%, and preferably less than 3% is in the form of docosahexaenoic acid (DHA); useful for treating psychological and nervous system disorders
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183379 Kits for determining risk of Alzheimer's disease
12/05/2002	US20020183375 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms
12/05/2002	US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183361 Heterocyclic sulfonamide inhibitors of beta amyloid production
12/05/2002	US20020183355 Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
12/05/2002	US20020183354 For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders
12/05/2002	US20020183353 For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse
12/05/2002	US20020183352 Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
12/05/2002	US20020183351 For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse

1 ... 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 ... 1833